ANDA 77106, held by Zydus. Sertraline Hydrochloride.
As of Nov 16, 2026, ANDA 77106 (Sertraline Hydrochloride), held by Zydus, was first approved by FDA on Feb 6, 2007, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 6, 2007 | Original application | Approved | None posted |
| Sertraline HydrochlorideEQ 25MG BASE · tablet;oral | Sertraline Hydrochloride | Discontinued |
| Sertraline HydrochlorideEQ 50MG BASE · tablet;oral | Sertraline Hydrochloride | Discontinued |
| Sertraline HydrochlorideEQ 100MG BASE · tablet;oral | Sertraline Hydrochloride | Discontinued |
| Feb 21, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 21, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| May 21, 2012 | Supplement 5Labeling | Approved | None posted |
| Sep 28, 2009 | Supplement 4Labeling | Approved | None posted |
| Sep 24, 2008 | Supplement 3Labeling | Approved | None posted |
| Mar 10, 2008 | Supplement 2Labeling | Approved | None posted |
| Aug 23, 2007 | Supplement 1Labeling | Approved | None posted |
| Feb 6, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters